Skip to main content

Site notifications

Notice for mRNA-1345 (for Respiratory Syncytial Virus (RSV) pre-fusion F protein (Moderna Australia Pty Ltd)

Active ingredients
mRNA-1345 (for Respiratory Syncytial Virus (RSV) pre-fusion F protein
Date of review outcome
Lapse date
Type
Priority review
Indication
Prevention of Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), initially in adults ≥ 60 years of age
Therapeutic area
Vaccines

Help us improve the Therapeutic Goods Administration site